|
|
 |
|
Viewing report
|
|
|
|
Strategic Perspectives: Antidyslipidemics - Current Market is not Conducive for Growth
Datamonitor, Oct 2008, Pages: 223
The antidyslipidemic market is increasingly governed by cost concerns which appear to be more pressing than the safety and efficacy concerns. Cost-saving initiatives together with the continuing genericization are going to bring the antidyslipidemic revenues down by 25% from $26.6 billion in 2007 to $19.9 billion in 2017.
Scope
- Description of the competitive landscape in antidyslipidemics market with detailed overview of main challenges for launched and novel agents.
- Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
- Analysis of major events and brand dynamics affecting the antidyslipidemics market, including the overview of the pipeline drugs.
Highlights of this title
The patent expiry of Zocor in 2006 in the US steepened the drastic revenue fall. With Lipitor losing its patent protection within the next five years, the market is expected to shrink further to $19.9bln by 2017 and become even harder to enter. In strong relation to this is Pfizers decision to exit the CV development.
The US FDA has been becoming ever more conservative over the recent years. Its recent tightening of the approval process has resulted in the non-approval of Cordaptive (Tredaptive) in the US. This is the first time in the history of antidyslipidemic development that a drug approval may be delayed until the outcome data are available.
The current late-stage pipeline offers a number of SPCs, which is an eloquent marker of a certain degree of stagnation in the development of novel agents, as it is now associated with more risks than before, due to the torcetrapibs failure in 2006, as well as the non-approval of Cordaptive in the US this year.
Key reasons to purchase this title
- Quantify the future size and understand the background of the antidyslipidemic market
- Quantify the impact of the recent ENHANCE results on the dynamics of the market
- Size up the potential for the market expansion and revenue increases that recent guidelines, initiatives and regulatory changes may bring.
Customers who bought this item also bought
Forecast Insight: Dyslipidemia - Genericization and Negative Trial Data Drive Market Shrinking
Commercial Insight: Antidyslipidemics - The competitive cost-conscious antidyslipidemics market presents challenges
The World Market for Gynaecology, 2007-2017
Commercial Insight: Antidyslipidemics - Branded Statins Beware, Generics Are Amongst You
Antidyslipidemics - Genericization and Negative Trial Data Drive Market Shrinkage
Commercial Insight: Targeted Therapy Cancer Brands - High Growth Market will see Eight New Blockbusters by 2017
Antidyslipidemics - The Power Of Two
Generics Series: Generics Trends in the Seven Major Markets and Beyond
Pipeline Insight: Antidyslipidemics - The Power of Two
Forecast Insight: Antihypertensives - Key Patent Expiries Prevent Market Growth
Commercial Insight: Cardiovascular and Metabolic Market Overview Diabetes to the Fore as Generics Hit Primary Care Markets
Forecast Insight: Antidiabetics - Switching to New Molecule Antidiabetics Drives Market Growth
|
|
|
|
